醋硝香豆素(Acenocoumarol) - 药物靶点：NQO1 x VKOR_在研适应症：血栓栓塞_专利_临床

概要

基本信息

药物类型

小分子化药

别名

3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin、3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin、3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin

+ [21]

靶点

NQO1 x VKOR

作用机制

NQO1抑制剂(苯醌还原酶-1抑制剂)、VKOR抑制剂(维生素K环氧化物还原酶复合体1抑制剂)、维生素K拮抗剂

治疗领域

心血管疾病

在研适应症

血栓栓塞

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C19H15NO6

InChIKeyVABCILAOYCMVPS-UHFFFAOYSA-N

CAS号152-72-7

关联

14

项与醋硝香豆素相关的临床试验

NCT03153150 / Completed临床3期IIT

Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage

Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation (OAC) result in a beneficial net reduction of all serious vascular events compared with not starting OAC?
Trial design: Investigator-led, multicentre, randomised, open, assessor-masked, parallel group, clinical trial of investigational medicinal product (CTIMP) prescribing strategies. Investigators plan for a pilot phase, followed by a safety phase.

开始日期2018-03-28

申办/合作机构

The University of Edinburgh

[+1]

EUCTR2016-003086-25-NL / Unknown status临床3期

More precise dosing of acenocoumarol in patients aged 80 and above, a pilot study - Eighty and a half

开始日期2017-04-19

申办/合作机构

University Medical Center Groningen

NCT02826200 / Unknown status临床4期IIT

Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography

The RETORIC study is a prospective cohort study with a primary aim to assess the incidence and independent predictors of reduced leaflet motion and valve thrombosis after TAVI procedure using multimodality imaging strategy comprising cardiac CT, transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE). As a secondary aim we will assess the incidence of stroke and transient ischemic attack (TIA) in patients with reduced leaflet motion and/or thrombosis when compared with those with normal leaflet function. In addition we will randomize patients with reduced leaflet motion and/or valve thrombosis to single antiplatelet therapy plus oral anticoagulation therapy versus standard therapy.
The primary outcome of the nested randomized trial will be the presence of reduced leaflet motion and/or valve thrombosis after 4 months, the secondary outcome is the presence of ischemic changes in brain demonstrated by MRI.

开始日期2016-07-01

申办/合作机构-

100 项与醋硝香豆素相关的临床结果

登录后查看更多信息

100 项与醋硝香豆素相关的转化医学

登录后查看更多信息

100 项与醋硝香豆素相关的专利（医药）

登录后查看更多信息

1,415

项与醋硝香豆素相关的文献（医药）

2024-12-01·Radiology Case Reports

Parietal hematoma of the small bowel due to anticoagulant overdose: A case report

Article

作者: Ndong, Abdourahmane ; Niang, Fallou Galas ; Diop, Abdoulaye Ndoye ; Faye, Ibrahima ; Diop, Ndeye Rokheya ; Sarr, Ndiame ; Konaté, Ibrahima ; Diallo, Adja Coumba ; Beye, Serigne Mor

Anticoagulant-induced spontaneous small bowel hematoma is a rare cause of acute mechanical bowel obstruction. We report the case of a 77-year-old patient with complete arrhythmia due to atrial fibrillation under acenocoumarol 4mg daily who was seen for right iliac fossa pain. The laboratory tests showed a prothrombin rate (PT) of 12%, an International Normalized Ratio (INR) of 6, and an aPTT (activated partial thromboplastin time) of 43 seconds. Abdominopelvic ultrasound showed an echogenic pelvic effusion. The diagnosis of the small hematoma was made by abdominopelvic CT scan, which showed a thickening of the small bowel wall reducing its caliber associated with a parietal hematoma . The evolution was unremarkable under supplementation therapy vitamin K.

2024-12-01·Annales de Cardiologie et d'Angéiologie

La fibrillation atriale à l'Hôpital Principal de Dakar au Sénégal : résultats et limites de la prise en charge

Article

作者: Khadidiatou, Dia ; Cherif, Mboup Mouhamed ; Madjiguène, Ka Mame ; Niang, Mboup Waly ; Marième, Diop ; Rabab, Yassine ; Tidiane, Ndao Serigne Cheikh

OBJECTIVESThe aim of the study was to determine the prevalence of AF in the cardiology department of the Hospital Principal of Dakar, then to evaluate the clinical, paraclinical, etiological and evolutionary profiles of AF and finally to identify the limits of its management in our context.PATIENTS AND METHODSThis was a retrospective, descriptive, analytical, mono-centric study carried out at Hospital Principal of Dakar from January 2019 to August 2021. Were included, all patients admitted for atrial fibrillation, or patients who presented an atrial fibrillation during hospitalization, confirmed by electrocardiogram or long-term electrocardiographic recording during the study period.RESULTSThe prevalence of atrial fibrillation during the period of our study compared to the hospital population was 7.71%, with a sex ratio of 1.03. The mean age was 67.88 ± 14.09 years. We noted that 83.64% of patients had at least one cardiovascular risk factor, with 56.36% suffering from hypertension, 50.91% of sedentary person and 23.64% of diabetics. Clinically, 92.72% of the patients were symptomatic, with dyspnea predominating (70.91%). Cardiac arrhythmia was present in 85.45% of patients, and congestive heart failure in 47.27%. Long-term electrocardiographic recording was performed in 10 patients, showing 50% of paroxysmal atrial fibrillation. Sixty-three patients (57.27%) had permanent AF, twenty-three patients (20.91%) had persistent AF, fourteen patients (12.73%) had long-term persistent AF and ten patients (9.09%) had paroxysmal AF. Transthoracic echocardiography showed 57.27% of left atrial dilatation and 72.3% of reduced left ventricular ejection fraction. Etiologies for cardiac causes were dominated by dilated cardiomyopathy (21.82%), followed by ischemic heart disease (17.27%). In terms of treatment, the most commonly used molecule was bisoprolol (38.18%), followed by digoxin (21.81%). Anticoagulants were used in 85.46% of cases. Acenocoumarol alone was used in 69.09% of patients. Drug-induced cardioversion was attempted in 2 patients without success, and 4 patients benefited from external electric shock with 3 successes. Most patients had a favorable outcome, but 34.54% suffered hemodynamic complications (18.18%) and thromboembolic ones as well (16.36%). In-hospital mortality in our series was 20%. It was significantly related to heart failure, with a left ventricular ejection fraction < 35% (p < 0.001).CONCLUSIONAtrial fibrillation is serious because of its hemodynamic, thromboembolic and rhythmic complications. The high mortality is explained by the underlying condition, but also by the delay in management with late diagnosis and, above all, the unavailability of ablation procedures in our context.

2024-10-15·Farmacéuticos Comunitarios

Análisis y categorización de las consultas farmacoterapéuticas recibidas en un Centro de Información de Medicamentos de Valencia

Article

作者: Romero Crespo, Isabel ; Montesinos, MC ; Lucas-Domínguez, R ; Romero Crespo, I ; Montesinos, M Carmen ; Gutiérrez-Igual, S ; Gutiérrez-Igual, Salvador ; Lucas-Domínguez, Rut

IntroductionDrug Information Services (DIS) act as a source of technical and scientific information of drugs and medical devices, promoting their rational use.ObjectiveTo analyze and classify, according to standardized criteria, the pharmacotherapeutic queries, therapeutic groups, and drugs most frequently consulted at the DIS of the Muy Ilustre Colegio Oficial de Farmacéuticos de Valencia (MICOF).MethodologyAn ambispective and cross-sectional observational study was conducted from June 1, 2021, to June 1, 2022. A total of 445 inquiries made by pharmacists from the province of Valencia were registered and analyzed, collecting the following data: drug, ATC-4 therapeutic group, and pharmacotherapeutic category of the query.ResultsThe most frequently consulted categories were commercialization and safety, with Proton Pump Inhibitors (PPIs, A02BC) and Vitamin K Antagonists (VKAs, B01AA) being the most consulted pharmacological groups, accounting for 2.7% and 2.3% of the total inquiries respectively. Regarding classification, 90,0% of the inquiries about acenocoumarol were about drug interactions, while 33.3% of the inquiries about PPIs were related to commercialization.ConclusionsThe analysis of the inquiries received has made possible to identify the therapeutic groups, drugs and pharmacotherapeutic categories that generate the highest number of inquiries. This information is valuable for improving the efficiency of responses at the DIS, providing uniformity, and reducing errors. Additionally, it provides a comprehensive database that facilitates the standardized integration of information.

100 项与醋硝香豆素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07064	醋硝香豆素	B01AA07	DB01418

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
血栓栓塞	-	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02696226 (CTgov)	N/A	血栓形成 \| 主动脉瓣疾病	3	SAVR Warfarin (SAVR Warfarin Arm)	鏇製醖遞構餘製醖廠鹹(廠衊鬱觸憲獵餘願襯蓋) = 夢淵鹽襯獵積鹽窪選鏇夢製積艱醖醖簾構窪壓 (壓構鑰廠壓齋窪築廠鏇, 製鹽觸製網壓廠獵餘憲 ~ 衊醖壓遞餘網積願願範) 更多	-	2017-11-08
				Warfarin+clopidogrel (TAVR Warfarin and Clopidogrel Arm)	鏇製醖遞構餘製醖廠鹹(廠衊鬱觸憲獵餘願襯蓋) = 鹹艱襯構醖願範鹹糧築夢製積艱醖醖簾構窪壓 (壓構鑰廠壓齋窪築廠鏇, 膚製鹹壓醖構獵餘廠窪 ~ 壓遞鏇鏇壓選膚製醖願) 更多